Core Viewpoint - The Guangdong Securities Regulatory Bureau plans to impose a total fine of 24.15 million yuan on China Railway Group and related personnel for recent violations after the company's delisting from the A-share market [1][5]. Group 1: Regulatory Actions - China Railway Group received an administrative penalty notice from the Guangdong Securities Regulatory Bureau for new violations occurring after its delisting [1][5]. - The company triggered the delisting conditions by having its stock price below 1 yuan for 20 consecutive trading days, leading to its official delisting on August 27, 2024 [3][5]. Group 2: Violations and Penalties - The violations include failure to disclose related party transactions amounting to approximately 1.1 billion yuan, inflating inventory by 600 million yuan, and misreporting cash holdings by 50 million and 70 million yuan in different reports [5][7]. - The total penalties include 5 million yuan for the company, 9.5 million yuan for the actual controller, and additional fines for other responsible personnel, totaling 24.15 million yuan [5][6]. Group 3: Previous Penalties - In May 2024, the company faced a total fine of 26.2 million yuan for serious information disclosure violations, including undisclosed large fund occupations and financial fraud [7]. - The actual controller was banned for life from the market, and the financial director received a five-year ban from serving in listed companies [7][8].

Group 1 - The stock price of Feikai Materials as of August 21, 2025, is 23.12 yuan, down 0.94 yuan from the previous trading day's closing price, representing a decline of 3.91% [1] - The opening price for the day was 24.06 yuan, with a highest price of 24.08 yuan and a lowest price of 22.93 yuan, and the trading volume reached 461,291 hands with a total transaction amount of 1.077 billion yuan [1] - Feikai Materials operates in the electronic chemicals industry, focusing on the research, production, and sales of electronic-grade chemicals, primarily used in semiconductors, flat panel displays, and LEDs [1] Group 2 - On August 20, the Shanghai Financial Court and the Shanghai Securities Regulatory Commission announced a regulatory enforcement case involving Feikai Materials' controlling shareholder and their concerted actors, who were fined and confiscated 7.67 million yuan for illegal reduction of holdings [1] - The net outflow of main funds for Feikai Materials on August 21 was 195.6752 million yuan, accounting for 1.5% of the circulating market value, while the net outflow over the past five days totaled 347.0452 million yuan, representing 2.66% of the circulating market value [1]

登录新浪财经APP 搜索【信披】查看更多考评等级 退市绝不是逃避责任的避风港。 去年8月已在A股退市的华铁股份8月21日公告称，8月20日，公司、实际控制人及相关当事人收到广东 证监局出具的《行政处罚事先告知书》。 根据《行政处罚事先告知书》，华铁股份、公司时任董事长宣瑞国涉嫌信息披露违法违规一案，已由广 东证监局调查完毕。广东证监局依法拟对公司及13名当事人作出行政处罚，合计罚款金额超2400万元。 《行政处罚事先告知书》显示，华铁股份涉案期间有关董事、监事、高级管理人员涉嫌违反证券法第八 十二条第三款的规定，构成证券法第一百九十七条第二款所述"直接负责的主管人员和其他直接责任人 员"。 其中，宣瑞国作为华铁股份时任董事长，组织实施关联交易，知悉相关资金划转对会计处理、财务记账 存在重大影响，未审慎关注亚通达设备记账完整情况；张璇作为华铁股份时任财务总监、副总经理，知 悉、参与华铁股份关联交易。知悉相关资金划转对会计处理、财务记账存在重大影响，未审慎关注亚通 达设备记账完整情况，2人是对华铁股份上述三项信息披露违法行为直接负责的主管人员。 涉嫌三项信息披露违法 《行政处罚事先告知书》显示，华铁股份未按规定披 ...

退市绝不是逃避责任的避风港。 根据《行政处罚事先告知书》，华铁股份、公司时任董事长宣瑞国涉嫌信息披露违法违规一案，已由广 东证监局调查完毕。广东证监局依法拟对公司及13名当事人作出行政处罚，合计罚款金额超2400万元。 涉嫌三项信息披露违法 去年8月已在A股退市的华铁股份8月21日公告称，8月20日，公司、实际控制人及相关当事人收到广东 证监局出具的《行政处罚事先告知书》。 2023年1月至2024年2月，华铁股份及其子公司北京全通达科技发展有限公司(以下简称"北京全通达")、 青岛亚通达铁路设备有限公司(以下简称"亚通达设备")、山东嘉泰交通设备有限公司与青岛恒超机械有 限公司(以下简称"青岛恒超")等4家关联企业发生关联方非经营性资金往来，实际代青岛恒超偿还保理 融资债务。相关资金流入到关联方11.34亿元，从关联方转回3.51亿元。其中，2023年1月至6月，流入到 关联方10.81亿元、占当期报告记载净资产的比例为34.01%，从关联方转回3.43亿元。 根据相关规定，上述关联交易事项属于应当及时披露的重大事件，并应当在定期报告中披露。华铁股份 未按规定及时披露上述事项。也未在2023年半年度报告进行 ...

Core Viewpoint - Recent incidents of information disclosure violations and arrests of executives in A-share listed companies have raised concerns about corporate governance and compliance in the market [2][3][4]. Group 1: Executive Arrests and Investigations - Multiple companies, including Keda Data, Kesi Technology, Tianyu Digital Science, and others, have announced significant issues, with executives facing investigations and arrests for various offenses [2][3]. - In August alone, six A-share listed companies reported issues with their core management, involving detention, arrest, and other coercive measures [3]. Group 2: Information Disclosure Violations - Four companies, including *ST Dongtong and *ST Gaohong, have been flagged for serious information disclosure violations, with some facing the risk of forced delisting due to major legal infractions [4][6]. - *ST Gaohong was found to have inflated revenue by nearly 20 billion and was fined 135 million, with several executives penalized [5]. - *ST Dongtong has been investigated twice this year for financial misreporting, facing high delisting risks [6]. Group 3: Company-Specific Issues - Jihua Group has been investigated for repeated information disclosure violations, indicating a pattern of non-compliance [7]. - Haosai has faced scrutiny for failing to disclose the arrest of its controlling shareholder and is under investigation for alleged bribery [8]. - As of August 19, the total market capitalization of the companies involved in these incidents is approximately 128.7 billion [9].

Core Viewpoint - The stock price of Nord New Materials Co., Ltd. experienced an abnormal fluctuation, with a cumulative increase of 20% over three consecutive trading days in August 2025, prompting regulatory scrutiny [2][4]. Group 1: Stock Trading Abnormalities - The company's stock price rose by a cumulative 20% on August 15, 18, and 19, 2025, indicating abnormal trading behavior as per Shanghai Stock Exchange regulations [2][4]. - The stock price increased by 33.18% from August 14 to August 19, 2025, while the relevant industry index only rose by 3.99% during the same period [8]. Group 2: Financial Performance - In 2024, the company reported a revenue of 5.277 billion, a year-on-year increase of 15.44%, but incurred a net loss of 352 million [5]. - For the first quarter of 2025, the company achieved a revenue of 1.409 billion but reported a net loss of 38 million [5]. - Preliminary estimates suggest a net loss of approximately 70 million for the first half of 2025, with a net loss of around 82 million after excluding non-recurring items [5]. Group 3: Regulatory Issues - The company and its chairman, along with other executives, received a notice from the China Securities Regulatory Commission regarding suspected violations of information disclosure laws [3][9]. - The company is cooperating with the investigation and has not yet received a conclusive opinion on the matter [9]. Group 4: Management Assurance - The board of directors confirmed that there are no undisclosed significant matters that could affect stock trading, and all required disclosures have been made [12].

浙江证监局指出，思创医惠时任董事长、总经理章笠中违法情节严重，该局拟决定：对章笠中采取10年 市场禁入措施。自浙江证监局宣布决定之日起，在禁入期间内，除不得继续在原机构从事证券业务或者 担任原上市公司、非上市公众公司董事、监事、高级管理人员职务外，也不得在其他任何机构中从事证 券业务或者担任其他上市公司、非上市公众公司董事、监事、高级管理人员职务。 中国经济网北京8月18日讯思创医惠（300078）(300078.SZ)15日发布关于收到杭州市公安局调取证据通 知书的公告。2025年8月14日，思创医惠收到杭州市公安局出具给公司的《调取证据通知书》【杭公 (经)调证字[2025]00481号】。《调取证据通知书》显示，杭州市公安局侦办的公司等涉嫌欺诈发行证券 案需调取公司有关证据材料。 截至目前，上述案件尚处于公安机关侦查阶段，尚未有明确结论。公司将积极配合公安机关的调查取证 工作。 思创医惠2023年9月发布公告称，公司于2023年9月25日收到中国证券监督管理委员会浙江监管局下发的 《行政处罚及市场禁入事先告知书》(浙处罚字[2023]28号)。 思创医惠涉嫌欺诈发行及信息披露违法违规一案，已由浙江证监局 ...

Group 1 - The core issue involves a fraud investigation against the company by the Hangzhou Public Security Bureau regarding the alleged fraudulent issuance of securities [1] - The company has previously been under investigation by the China Securities Regulatory Commission (CSRC) for information disclosure violations, leading to administrative penalties [3] - The company was found to have fabricated significant false information in its public bond issuance documents, resulting in inflated revenue and profits for the years 2019 and 2020 [3][4] Group 2 - The company was penalized with a fine of 85.7 million yuan and its former chairman and general manager received individual fines and a 10-year market ban [5] - The company has faced significant revenue declines and continuous losses due to intense industry competition and business adjustments [5] - The company completed the divestiture of its 100% stake in its subsidiary, Medical Technology Co., Ltd., in August 2025 [5]

Group 1 - The company, Lifan Shuke Co., Ltd., is undergoing an investigation by the China Securities Regulatory Commission (CSRC) for suspected violations of information disclosure laws, which may lead to a forced delisting if found guilty [1][2] - Shareholder Fan Li's 67,557,299 shares, representing 10.53% of the company's total shares, will be publicly auctioned on the JD.com judicial auction platform due to a debt dispute [1][2] - The auction is set to take place on September 30, 2025, and the shares being auctioned account for 99.9953% of Fan Li's total holdings [1][2] Group 2 - Following the auction, the total shares held by Fan Li and Fan Zhi may decrease from 137,824,715 shares to 70,267,416 shares, reducing their ownership percentage from 21.48% to 10.95% [2] - Neither Fan Li nor Fan Zhi are the controlling or largest shareholders of the company, and the auction of their shares will not result in a change of control or adversely affect the company's normal operations [2]

证券代码:300147 证券简称: 香雪制药 公告编号:2025-038 广州市香雪制药股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 雪制药"）及公司实际控制人王永辉收到中国证券监督管理委员会（以下简称"中 国证监会"）下发的《立案告知书》（编号：证监会立案字 0062024028 号、编 号：证监会立案字 0062024029 号），因涉嫌信息披露违法违规，根据《中华人 民共和国证券法》、《中华人民共和国行政处罚法》等法律法规，中国证监会决 定对公司及王永辉立案。2025 年 3 月 21 日，公司收到中国证监会发出的《行政 处罚事先告知书》（广东证监处罚字〔2025〕5 号）。以上具体内容详见公司分 别于 2024 年 9 月 30 日、2025 年 3 月 21 日在巨潮资讯网披露的《关于公司及实 际控制人收到中国证券监督管理委员会立案告知书的公告》 （公告编号:2024-051） 和《关于公司及相关当事人收到 <行政处罚事先告知书> 的公告》 （公告编号:2025- 近日，公司及相关当事人收到中国证券监督管理委员会广东监管局发出的 《行 ...